ARPA-H launched THRIVE, a multi-team, up-to-$160 million effort intended to accelerate bespoke gene-editing therapies for rare genetic pediatric diseases. The program, announced by the U.S. health research agency, is structured around multiple technological approaches and clinical trial designs, with teams expected to initiate clinical trials by year three. THRIVE is positioned as a pipeline-building mechanism rather than a single-project grant: it funds different teams pursuing distinct rare-disease targets and delivery strategies across organ systems. That approach is meant to compress timelines from preclinical validation into clinical proof-of-concept. For gene-editing developers, the announcement signals continued U.S. public investment in platform-ready manufacturing and trial execution models for custom therapies. It also raises the bar for operational readiness—teams will need regulatory-grade protocols, manufacturing workflows, and monitoring plans capable of scaling to early clinical timelines. Overall, THRIVE expands ARPA-H’s role as a catalyst for first-in-human velocity in rare disease, supporting a landscape that has already seen multiple bespoke gene therapy entrants but remains constrained by time, cost, and regulatory complexity.